The risk for anemia with targeted therapies for solid tumors

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Anemia is a frequent complication in cancer patients.
• The specific risks of anemia associated with targeted cancer therapies remain largely uncharacterized.

Purpose of the Study:

• To determine the incidence and relative risk of anemia in patients with solid tumors treated with targeted therapies.
• To compare anemia risk between targeted therapy regimens and standard treatments.

Main Methods:

• A meta-analysis of randomized controlled trials involving patients with solid tumors was conducted.
• Targeted therapies (alone or in combination) were compared against standard therapy alone.
• Incidence and relative risk (RR) for anemia events were calculated for 24,310 patients.

Main Results:

• Targeted therapies increased the risk of all grades of anemia by 7% compared to standard treatment.
• Biological therapies alone, but not in combination with chemotherapy, showed a higher RR for all grades (44%) and grades 1-2 (38.9%) anemia.
• Significant anemia risk was noted for erlotinib, trastuzumab, and sunitinib, while bevacizumab showed a lower risk. Tyrosine kinase inhibitors (RR 1.33) and anti-EGFR (RR 1.24) agents increased risk.

Conclusions:

• Grade 1-2 anemia is common with biological agents, especially small-molecule tyrosine kinase inhibitors (e.g., gefitinib, erlotinib) in breast and lung cancers.
• Bevacizumab demonstrated a reduced risk of anemia.
• Erythropoiesis-stimulating agents are not approved for use with targeted therapies without concurrent chemotherapy, and supportive care is the recommended approach.